Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Secukinumab vs Etanercept and Placebo in Moderate to Severe Chronic Plaque Psoriasis
NCT01900782Phase 3Withdrawn
- Sponsor
- Novartis
- Start
- Oct 2013
- Primary completion
- Jun 2015
- Modality
- Monoclonal Antibodies
01
Overview
A Phase 3 trial of secukinumab in psoriasis, sponsored by Novartis. Planned start Oct 2013; status: withdrawn.
02
Drugs
secukinumab
03
Conditions
psoriasis
Beyond the preview
Go deeper on NCT01900782.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT01900782.